RNA is expected to report earnings to fall -2.32% to -81 cents per share on May 07

A.I.dvisor
at Tickeron.com
05/06/24
Loading...
RNA - Avidity Biosciences
Avidity Biosciences Earnings Graph
Q1'24
Est.
$-0.81
Q4'23
Missed
by $0.13
Q3'23
Beat
by $0.04
Q2'23
Beat
by $0.13
Q1'23
Beat
by $0.10
The last earnings report on December 31 showed earnings per share of -79 cents, missing the estimate of -66 cents. P/B Ratio (5.051) is normal, around the industry mean (10.296). P/E Ratio (0.000) is within average values for comparable stocks, (116.129). RNA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.466). RNA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (200.000) is also within normal values, averaging (233.055). With 641.65K shares outstanding, the current market capitalization sits at 2.53B.
View a ticker or compare two or three
RNADaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which engages in the research and development of biopharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
10578 Science Center Drive
Phone
+1 858 401-7900
Employees
253
Web
https://www.aviditybiosciences.com